Author Login IJIRT Partner Network (IPN) Login

Recent advancements in treatment of cystic fibrosis

  • Unique Paper ID: 160674
  • Volume: 10
  • Issue: 1
  • PageNo: 978-987
  • Abstract:
  • Cystic fibrosis (CF) is the most usual life-shortening autosomal recessive disease(1). It is generally result of mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene (2) . This result into the accumulation of exocrine secretions in various systems, specifically the respiratory, and gastrointestinal systems, causing serious comorbidities(5). Still, lung disorder accounts for important reason for the excessive morbidity and mortality in CF(6)Cystic fibrosis also influences epithelial cell lining of reproductive tract and lead to faulty exocrine secretion.Patients with cystic fibrosis have regular gastrointestinal issues like Fatty liver , Rectal prolapse , Constipation , malabsorption , Distal intestinal obstruction syndrome, Gastro-oesophageal reflux , etc(3). Most general CF-causing mutation is F508del. Other CFTR mutations may additionally impair mRNA and protein expression, function, stability or a combination of these. Gene modifiers, social status, patient's lifestyle, respiratory infections and adherence to treatment plans like quite a few different elements impact disorder severity beyond CFTR mutations. Most of the new drugs availablee in market for CF remedy have been deliberate and developed from acquired advances on genetics and proteomics(6) Kalydeco® (Ivacaftor),is a drug referred to as a CFTR “potentiator” was at the beginning supposed for use in the therapy of patients with the G551D mutation in Cystic Fibrosis(7).Research is being carried out into gene therapy that aims at introducing a normal copy of CFTR into lung epithelial cells.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 10
  • Issue: 1
  • PageNo: 978-987

Recent advancements in treatment of cystic fibrosis

Related Articles

13 Jan, 2024

Formulation & Evaluation of Polyherbal solution for Prognosis of IgA Vasculitis.

Read More
31 Aug, 2023

Medicinal and Therapeutic agent : Mushrooms

Read More
Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry